# Karuna Therapeutics, Inc. – Consensus ‘buy’ rating and 49.9% Upside Potential

- Link: https://www.directorstalkinterviews.com/karuna-therapeutics-inc.consensus-buy-rating-and-49.9-upside-potential/4121127538
- Published: 2023-09-19T13:32:36+01:00
- Author: Charlotte Edwards

**Karuna Therapeutics, Inc.** with ticker code (KRTX) now have 18 confirmed analysts
covering the stock with the consensus suggesting a rating of ‘buy’. The target price
High/Low ranges between 332 and 197 calculating the mean target price we have $271.11.
Now with the previous closing price of $180.90 this indicates there is a potential
upside of 49.9%. The 50 day moving average now sits at $189.24 while the 200 day
moving average is $199.92. The total market capitalization for the company now stands
at 6.45B. The stock price for the company is currently 171.13 USD

 The potential market cap would be $9,660,584,100 based on the market consensus.

The company has a dividend yield of 2.93%. Other points of data to note are a P/
E ratio of -, revenue per share of 0.17 and a -25.87% return on assets.

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company
creates and delivers transformative medicines for people living with psychiatric
and neurological conditions. Its pipeline is primarily built on the therapeutic 
potential of its product candidate, KarXT (xanomeline-trospium), an oral modulator
of muscarinic receptors that are located both in the central nervous system (CNS),
and various peripheral tissues. KarXT combines xanomeline, a novel muscarinic agonist,
with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic
receptors in the CNS. The Company is developing KarXT for the treatment of acute
psychosis in adults with schizophrenia, as well as for the treatment of psychosis
in Alzheimer’s disease (AD). The Company is also engaged in developing its investigational
TRPC4/5 candidate, KAR-2618, for the treatment of mood and anxiety disorders, and
plan to provide details regarding the expected development of KAR-2618.

Share on: